TEL AVIV, Israel, Oct. 7, 2024 /PRNewswire/ -- Medinol Ltd. is
pleased to announce the successful First-in-Human (FIH)
implantation of the ChampioNIR Drug-Eluting Peripheral Stent by Drs
Gerard S.Goh and Thodur Vasudevan of
the Alfred Hospital in Melbourne
Australia, introducing a revolutionary advancement in the
mechanics, durability and drug delivery of peripheral drug eluting
stents.
The ChampioNIR Drug-Eluting Peripheral Stent System poses a
transformational technology designed to improve patient outcomes
and procedural success. In a first of its kind hybrid mechanical
design, radial support is provided by the metallic component of the
stent, whereas longitudinal structure is provided by a
bioresorbable polymeric mesh providing unsurpassed flexibility and
long-term durability in even the most challenging anatomies.
Furthermore, a unique drug-elution paradigm releases drug from the
entire cylindrical area of the stent, drastically reducing
diffusion distances and allowing, for the first time, therapeutic
dosing of a large peripheral vessel with a 'limus' drug for an
extended period of time.
"We were impressed with ChampioNIR's deliverability and its
straightforward deployment", said Prof. Gerard S Goh, Head of
Interventional Radiology at The Alfred Hospital. "The Frictionless
Deployment Mechanism made the precise positioning of the stent very
straightforward".
Dr. Yoram Richter, CEO of Medinol, added: "Medinol is
excited to bring to clinical practice the culmination of years of
research and development into novel stent designs, tailor-made for
unmet clinical challenges in vascular interventions".
The CHAMPIONSHIP First In Human study will enroll a total of 30
patients across 7 sites in Australia and the United States. Prof.
Sahil Parikh, PI of the CHAMPIONSHIP
study commented "The ChampioNIR stent represents a breakthrough in
treatment for SFA lesions. I am excited to see this device come to
life after years of development."
About Medinol
Founded in 1992, Medinol is a privately held company with
offices in the U.S. and Israel,
employing over 300 people.
Extending more than 30 years of experience in the stent market,
Medinol is aggressively changing paradigms in how disease states
are diagnosed and treated. By designing cutting edge scaffolds for
stenting multiple areas of the human body, dramatically reducing
complications in Structural Heart procedures and providing real
time insights into physiological metrics through Implantable
Microsensors, Medinol looks years into the future to create
pioneering medical devices. For more information, see
www.medinol.com.
Contact: Jeff Roach
jeffr@medinol.com
Logo -
https://mma.prnewswire.com/media/1894777/Medinol_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/medinol-announces-successful-first-in-human-implantation-of-championir-drug-eluting-peripheral-stent-system-in-australia-302267287.html